Tao Ye1, Xiaoqi Yang1, Peng Lv1, Haoran Liu1, Zhangqun Ye1. 1. Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Abstract
BACKGROUND: Several recent publications have evaluated the prognostic value of preoperative hydronephrosis (HN) in patients with upper tract urinary carcinoma (UTUC). The aim of this meta-analysis was to explore the pooled effect of preoperative HN on the prognosis of UTUC patients treated with radical nephroureterectomy (RNU) based on current evidence. METHODS: We performed a systematic search of Pubmed, Cochrane library, and Web of Science databases from inception to June 2020. The outcomes of interest included overall survival (OS), cancer-special survival (CSS), disease-free survival (DFS), and intravesical recurrence-free survival (IVRFS). RESULTS: Twenty-two studies with a total of 7,542 patients satisfied the eligibility criteria and were finally included in this meta-analysis. The percent of patients with preoperative HN varied in the eligible studies, ranging from 18 to 81%. The pooled results showed that preoperative HN was significantly associated with worse OS (P = 0.004), CSS (P < 0.001), and DFS (P = 0.005), but not IVRFS (P = 0.12). No obvious publication bias was detected by Begg's test in all the analyses. CONCLUSIONS: The results drawn in our meta-analysis suggest that the presence of preoperative HN is associated with worse prognosis in patients treated with RNU for UTUC. Therefore, closer surveillance and more aggressive therapy may be needed for UTUC patients present with preoperative HN. Well-designed prospective studies are necessary to substantiate the prognostic value of HN in UTUC.
BACKGROUND: Several recent publications have evaluated the prognostic value of preoperative hydronephrosis (HN) in patients with upper tract urinary carcinoma (UTUC). The aim of this meta-analysis was to explore the pooled effect of preoperative HN on the prognosis of UTUC patients treated with radical nephroureterectomy (RNU) based on current evidence. METHODS: We performed a systematic search of Pubmed, Cochrane library, and Web of Science databases from inception to June 2020. The outcomes of interest included overall survival (OS), cancer-special survival (CSS), disease-free survival (DFS), and intravesical recurrence-free survival (IVRFS). RESULTS: Twenty-two studies with a total of 7,542 patients satisfied the eligibility criteria and were finally included in this meta-analysis. The percent of patients with preoperative HN varied in the eligible studies, ranging from 18 to 81%. The pooled results showed that preoperative HN was significantly associated with worse OS (P = 0.004), CSS (P < 0.001), and DFS (P = 0.005), but not IVRFS (P = 0.12). No obvious publication bias was detected by Begg's test in all the analyses. CONCLUSIONS: The results drawn in our meta-analysis suggest that the presence of preoperative HN is associated with worse prognosis in patients treated with RNU for UTUC. Therefore, closer surveillance and more aggressive therapy may be needed for UTUC patients present with preoperative HN. Well-designed prospective studies are necessary to substantiate the prognostic value of HN in UTUC.
Authors: Eugene K Cha; Shahrokh F Shariat; Matthias Kormaksson; Giacomo Novara; Thomas F Chromecki; Douglas S Scherr; Yair Lotan; Jay D Raman; Wassim Kassouf; Richard Zigeuner; Mesut Remzi; Karim Bensalah; Alon Weizer; Eiji Kikuchi; Christian Bolenz; Marco Roscigno; Theresa M Koppie; Casey K Ng; Hans-Martin Fritsche; Kazumasa Matsumoto; Thomas J Walton; Behfar Ehdaie; Stefan Tritschler; Harun Fajkovic; Juan I Martínez-Salamanca; Armin Pycha; Cord Langner; Vincenzo Ficarra; Jean-Jacques Patard; Francesco Montorsi; Christopher G Wood; Pierre I Karakiewicz; Vitaly Margulis Journal: Eur Urol Date: 2012-01-23 Impact factor: 20.096
Authors: Jamie C Messer; John D Terrell; Michael P Herman; Casey K Ng; Douglas S Scherr; Benjamin Scoll; Stephen A Boorjian; Robert G Uzzo; Mark Wille; Scott E Eggener; Steven M Lucas; Yair Lotan; Shahrokh F Shariat; Jay D Raman Journal: Urol Oncol Date: 2011-09-09 Impact factor: 3.498
Authors: G Bozzini; L Nison; P Colin; A Ouzzane; D R Yates; F Audenet; G Pignot; A Arvin-Berod; O Merigot; L Guy; J Irani; F Saint; S Gardic; P Gres; F Rozet; Y Neuzillet; A Ruffion; M Roupret Journal: World J Urol Date: 2012-10-11 Impact factor: 4.226
Authors: Alison Birtle; Mark Johnson; John Chester; Robert Jones; David Dolling; Richard T Bryan; Christopher Harris; Andrew Winterbottom; Anthony Blacker; James W F Catto; Prabir Chakraborti; Jenny L Donovan; Paul Anthony Elliott; Ann French; Satinder Jagdev; Benjamin Jenkins; Francis Xavier Keeley; Roger Kockelbergh; Thomas Powles; John Wagstaff; Caroline Wilson; Rachel Todd; Rebecca Lewis; Emma Hall Journal: Lancet Date: 2020-03-05 Impact factor: 79.321